| 臺大學術典藏 |
2020-08-13T06:33:54Z |
Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers
|
Chang Y.-L.; Wu C.-T.; JIN-YUAN SHIH; Lee Y.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:54Z |
Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas
|
Chang Y.-L.;Wu C.-T.;Jin-Yuan Shih;Lee Y.-C.; Chang Y.-L.; Wu C.-T.; JIN-YUAN SHIH; Lee Y.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:52Z |
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction
|
Lee Y.-C.; Tsai M.-F.; Wu S.-G.; Chang Y.-L.; Lin J.-W.; Wu C.-T.; Chen H.-Y.; Yu C.-J.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-08-13T06:33:51Z |
EGFR and p53 status of pulmonary pleomorphic carcinoma: Implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy
|
Chang Y.-L.;Wu C.-T.;Jin-Yuan Shih;Lee Y.-C.; Chang Y.-L.; Wu C.-T.; JIN-YUAN SHIH; Lee Y.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:50Z |
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma
|
JIN-YUAN SHIH; Tsai T.-H.; Wu S.-G.; Chang Y.-L.; Wu C.-T.; Tsai M.-F.; Wei P.-F.; Yang C.-H.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:48Z |
The significance of visceral pleural surface invasion in 321 cases of non-small cell lung cancers with pleural retraction
|
Lee Y.-C.; Wu C.-T.; JIN-YUAN SHIH; Lin M.-W.; Chang Y.-L.;Lin M.-W.;Jin-Yuan Shih;Wu C.-T.;Lee Y.-C.; Chang Y.-L. |
| 臺大學術典藏 |
2020-08-13T06:33:45Z |
Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ?2 cm in maximal dimension
|
Lin M.-W.; Wu C.-T.; JIN-YUAN SHIH; Chang Y.-L.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Tsai T.-H.; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yang C.-Y.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.-H.;Yu C.-J.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; JIN-YUAN SHIH; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H.; JIN-YUAN SHIH; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu C.-L.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H. |
| 臺大學術典藏 |
2020-08-12T08:25:28Z |
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma
|
Tsai T.-H.;Shang-Gin Wu;Chang Y.-L.;Wu C.-T.;Tsai M.-F.;Wei P.-F.;Yang C.-H.;Yu C.-J.;Yang P.-C.;Shih J.-Y.; Tsai T.-H.; SHANG-GIN WU; Chang Y.-L.; Wu C.-T.; Tsai M.-F.; Wei P.-F.; Yang C.-H.; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T08:25:28Z |
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction
|
Shang-Gin Wu ;Chang Y.-L. ;Lin J.-W. ;Wu C.-T. ;Chen H.-Y. ;Tsai M.-F. ;Lee Y.-C. ;Yu C.-J. ;Shih J.-Y.; SHANG-GIN WU; Chang Y.-L.; Lin J.-W.; Wu C.-T.; Chen H.-Y.; Tsai M.-F.; Lee Y.-C.; Yu C.-J.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T06:35:35Z |
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
|
Gow C.-H.; Chang Y.-L.; Hsu Y.-C.; Tsai M.-F.; Wu C.-T.; CHONG-JEN YU; Yang C.-H.; Lee Y.-C.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T06:34:15Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Hsu C.-C.; Wu C.-T.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Wu C.-T.; Chang Y.-L.; Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:35Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:15Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Chang Y.-L.; Su K.-Y.; Hsu C.-L.; Liu Y.-N.; Chen K.-Y.; Tsai T.-H.; Liao W.-Y.; CHAO-CHI HO; Yang C.-Y. |
| 臺大學術典藏 |
2020-07-21T06:25:19Z |
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma
|
Yang P.-C.; Shih J.-Y.; Yu C.-J.; Yang C.-H.; TZU-HSIU TSAI; Wu S.-G.; Chang Y.-L.; Wu C.-T.; Tsai M.-F.; Wei P.-F. |
| 臺大學術典藏 |
2020-07-21T06:09:18Z |
The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms
|
Chang Y.-L.;Lee Y.-C.;Wei-Yu Liao;Wu C.-T.; Chang Y.-L.; Lee Y.-C.; WEI-YU LIAO; Wu C.-T. |
| 臺大學術典藏 |
2020-07-21T06:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Chen K.-Y.; Tsai T.-H.; Ho C.-C.; WEI-YU LIAO; Yang C.-Y.; Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liao B.-C.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C. |
| 臺大學術典藏 |
2020-07-21T05:40:34Z |
Programmed cell death-ligand 1 expression in surgically resected stage i pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
|
Yang P.-C.; Wu C.-T.; Chang Y.-L.; Lin M.-W.; CHING-YAO YANG; Ching-Yao Yang;Lin M.-W.;Chang Y.-L.;Wu C.-T.;Yang P.-C. |
| 臺大學術典藏 |
2020-07-21T05:40:32Z |
High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma
|
Yang P.-C.; Wu C.-T.; Lin M.-W.; CHING-YAO YANG; Chang Y.-L. |
| 臺大學術典藏 |
2020-07-21T05:40:31Z |
The Prognostic Significance of pSTAT1 and CD163 Expressions in Surgically Resected Stage 1 Pulmonary Squamous Cell Carcinomas
|
CHING-YAO YANG; Kuo S.-W.; Wu C.-T.; Chang Y.-L.; Yang P.-C.; Lin M.-W. |
| 臺大學術典藏 |
2020-07-21T05:40:30Z |
Globo H expression is associated with driver mutations and PD-L1 expressions in stage i non-small cell lung cancer
|
Lin M.-W.; Chang Y.-L.; Wu C.-T.; CHING-YAO YANG; Ching-Yao Yang;Lin M.-W.;Chang Y.-L.;Wu C.-T. |
| 臺大學術典藏 |
2020-07-21T05:40:29Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Lee J.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Ching-Yao Yang;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; CHING-YAO YANG; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H. |
| 臺大學術典藏 |
2020-07-05T01:54:04Z |
The role of endoplasmic reticulum stress-related unfolded protein response in the radiocontrast medium-induced renal tubular cell injury
|
Chiang C.K.; Liu S.H.; TE-I WENG; Tsai K.S.; Sheu M.L.; Wu C.T.; Wu C.T.;Sheu M.L.;Tsai K.S.;Te-I Weng;Chiang C.K.;Liu S.H. |
